1,721,033 research outputs found
Idraparinux: review of its clinical efficacy and safety for prevention andtreatment of thromboembolic disorders.
No full text1. Expert Opin Investig Drugs. 2008 May;17(5):773-7.
Idraparinux: review of its clinical efficacy and safety for prevention and
treatment of thromboembolic disorders.
Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L.
Department of Medical and Surgical Sciences, Thromboembolism Unit, University of
Padua, 35128 - Padua, Italy. [email protected]
BACKGROUND: Idraparinux is a synthetic pentasaccharide that binds to antithrombin
with high affinity. In view of its long half-life, it is suitable for once-a-week
administration.
OBJECTIVE: To review the evidence favoring the use of idraparinux for the acute
and long-term treatment of patients with venous thromboembolism (VTE) and for the
prevention of thromboembolic events in patients with atrial fibrillation (AF).
METHODS: All preclinical and clinical studies carried out with the use of
idraparinux were sought through electronic searches of MEDLINE from January 1,
1999 up to December 31, 2007.
RESULTS: The administration of idraparinux in subcutaneous fixed doses of 2.5 mg
once weekly was found to be as effective and safe as conventional antithrombotic
therapy in the initial treatment of patients with deep vein thrombosis, but less
effective than standard therapy in the initial treatment of patients with primary
pulmonary embolism. During a 6-month extension of thromboprophylaxis, idraparinux
was effective in preventing recurrent VTE but was associated with an increased
risk of bleeding versus placebo. Finally, in patients with AF the long-term
treatment with idraparinux was as effective as vitamin K antagonists, but caused
more bleeding.
CONCLUSIONS: In its current formulation, idraparinux can be recommended only for
the initial treatment of patients with deep vein thrombosis. The bioequipotency
of a biotinylated version of idraparinux (idrabiotaparinux), whose effects can be
reversed by a neutralizing agent (avidin), is under investigation in the
treatment of VTE at present, as is the use of lower doses in patients with AF.
PMID: 18447601 [PubMed - indexed for MEDLINE
The Risk of Cancer Progression in Women With Gynecological Malignancies andThrombophilic Polymorphisms: A Pilot Case-Control Study.
No full textClin Appl Thromb Hemost. 2009 Oct;15(5):535-9. Epub 2008 Jun 29.
The risk of cancer progression in women with gynecological malignancies and
thrombophilic polymorphisms: a pilot case-control study.
Tormene D, Beltramello P, Perlati M, Brandolin B, Barbar S, De Toffoli G, Simioni
P.
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine,
University of Padua Medical School, Padua, Italy. [email protected]
Cancer produces a hypercoagulable state, which might lead to thrombosis, and on
contrary, unprovoked venous thromboembolism might be the manifestation of an
occult cancer. In this pilot case-control study, we assessed the risk of
gynecological malignant diseases related to the presence of the factor V Leiden
and prothrombin G20210A polymorphisms. Fifty-two women underwent an operation for
gynecological malignancy and were enrolled in the study. Women who underwent an
operation for gynecological nonmalignant disease in the same days of cases were
considered as controls. The presence of factor V Leiden and prothrombin G20210A
was assessed in case and control groups. In all, 7 out of 52 cases were carriers
of the 2 polymorphisms compared with 20 out of 198 controls (odds ratio = 1.3;
95% confidence interval, 0.6-3.0). The results were also similar when the risk
was considered separately for the site of cancer. As for advanced and metastatic
malignancies, the odds ratios were 2.3 (95% confidence interval, 0.9-6.0) and 3.3
(95% confidence interval, 1.0-11), respectively, compared to noncancer patients.
When these 2 groups were compared to nonadvanced cancer group, the odds ratios
for carriers of polymorphisms were 2.7 (95%confidence interval, 0.7-11.0) and 3.9
(95%confidence interval, 0.8-18.6) for advanced cancer and metastatic
malignancies, respectively. Women with factor V Leiden or prothrombin G20210A
polymorphisms who developed gynecological malignancy might present with a higher
stage of cancer at the time of surgery. Larger case-control studies in similar
cohort of patients are needed to confirm these findings.
PMID: 18591179 [PubMed - indexed for MEDLINE
Successful haemorrhage menagement with highly purified vWF/FVIII concentrates as first line therapy in two patients affected by acquired haemophilia
No full text
Highly purified VWF/FVIII complex concentrates as first line therapy in three patients affected by acquired haemophilia A and cardiovascular disease
No full textCognitive dysfunctions and cerebral microbleeds in adult patients with haemophilia A: a clinical and MRI pilot-study.
No full textHigh dose of FVIII concentrate as first-line therapy in 4 patients affected by acquired hemophilia A and cardiovascular disease
No full textHigh dose of human plasma-derived FVIII-VWF as first line therapy in patients affected by acquired hemophilia A and concomitant cardiovascular disease
No full text
- …
